Vaxess Technologies News Releases

About

Formed in 2012, the company is developing its proprietary smart-release therapies based on technologies originally developed at Tufts University and MIT. Vaxess is a venture-funded company that is also supported by the NIH and NSF.
Formed in 2012, the company is developing its proprietary smart-release therapies based on technologies originally developed at Tufts University and MIT. Vaxess is a venture-funded company that is also supported by the NIH and NSF.

Press Contacts

Danielle Reisley
Media

Corporate Video

Resources (Files)

Enhancing humoral immunity via sustained-release implantable microneedle patch vaccination
Thin silk fibroin films as a dried format for temperature stabilization of inactivated polio vaccine

Executive Team

Michael has spent his career transforming complex technologies into transformational products. Prior to Vaxess, Michael spent time at Google and Honda where he helped bring a range of products to market and earned more than fifteen patents. Michael received his B.S. in Mechanical Engineering from Purdue University and his M.B.A. from Harvard.
https://cdn.filestackcontent.com/NGSfLmfYSxCqYPlFNz9e
Michael Schrader
Co-Founder, CEO
View more >>
With a background in chemistry and nanomaterials, Kathryn has focused on the translation of academic research breakthroughs into impactful products, working across disciplines of biology, chemistry, and engineering. Prior to co-founding Vaxess, Kathryn was a postdoctoral research fellow in the Department of Chemistry & Chemical Biology at Harvard. Kathryn began her career in research and development at Merck. She holds a BA in chemistry from Colby College and a PhD in Physical Chemistry from Northwestern University.
https://cdn.filestackcontent.com/aWqc7oPQS3iWmyLH59OW
Kathryn Kosuda, PHD
Co-Founder, Chief Scientific Officer
View more >>
Dr. Fruehauf is the Co-Founder and General Partner of BioInnovation Capital. He is also a Founder and current President and Executive Director of LabCentral, a launchpad for high-potential biotech startups. Prior to LabCentral, he founded Cambridge Biolabs, a contract research facility serving startup and virtual companies in Kendall Square. Dr. Fruehauf is also a Co-Founder of ViThera Pharmaceuticals, Deltix and Cequent Pharmaceuticals, and an advisor or board member to numerous life sciences companies and non-profits.
https://cdn.filestackcontent.com/lR7YZRFAQLSGZzFc2XpH
Johannes Fruehauf, MD, PhD
Co-Founder, General Partner BioInnovation Capital
View more >>

Social Accounts